HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin

Table 2 Humoral and neutralizing antibody response

Antigen			Control group			E6 group			E9 group			L6 group			L9 group
			Week 0	Week 48	P value	Week 0	Week 48	P value	Week 0	Week 48	P value	Week 0	Week 48	P value	Week 0	Week 48	P value
Humoral response
Capsid	IgM	Seroc	96.1	96.1	-	100.0	100.0	-	100.0	100.0	-	100.0	100.0	-	100.0	100.0	-
		Titer	108.9 ± 96.4	57.3 ± 81.9	0.002	269.3 ± 313.5	107.4 ± 105.3	0.003	210.8 ± 223.0	98.3 ± 104.2	0.008	310.5 ± 338.4	273.8 ± 530.7	ns	174.9 ± 182.5	170.7 ± 221.6	ns
	IgA	Seroc	84.6	73.1	ns	86.6	66.6	ns	86.6	86.6	-	92.8	85.7	ns	100.0	91.6	ns
		Titer	12.0 ± 20.8	10.0 ± 16.2	0.020	48.2 ± 76.9	23.6 ± 26.6	0.010	38.3 ± 49.2	29.3 ± 34.4	ns	34.1 ± 38.5	24.8 ± 41.3	0.006	30.3 ± 25.6	22.9 ± 26.9	ns
	IgG	Seroc	96.1	96.1	-	100.0	100.0	-	100.0	100.0	-	100.0	100.0	-	91.6	91.6	-
		Titer	30056.0 ± 39875.0	17913.7 ± 24413.0	< 0.001	49443.7 ± 40431.0	24135.7 ± 23793.0	0.002	30604.8 ± 22036.0	28932.5 ± 24813.0	ns	42400.4 ± 73634.0	31502.8 ± 62453.0	0.040	52700.6 ± 69336.1	33379.0 ± 52006.1	0.010
E2	IgM	Seroc	34.6	19.2	ns	33.3	26.6	ns	13.3	13.3	ns	57.1	35.7	ns	25.0	33.3	ns
		Titer	7.1 ± 3.5	9.7 ± 14.5	ns	7.8 ± 4.7	7.8 ± 2.4	ns	5.9 ± 2.0	5.9 ± 1.9	ns	8.7 ± 3.7	8.8 ± 5.5	ns	11.4 ± 19.1	9.4 ± 7.2	ns
	IgA	Seroc	15.3	11.5	ns	6.6	6.6	ns	6.6	0.0	-	14.2	0.0	-	0.0	0.0	-
		Titer	5.8 ± 1.8	5.6 ± 1.6	ns	5.3 ± 1.3	5.3 ± 1.3	ns	5.3 ± 1.3	5.00 ± 0	ns	5.7 ± 1.8	5.0 ± 0	ns	5.0 ± 0.0	5.0 ± 0.0	ns
	IgG	Seroc	61.5	80.7	ns	46.4	66.6	ns	86.6	86.6	ns	71.4	71.4	ns	66.6	83.3	ns
		Titer	325.9 ± 380.0	222.8 ± 221.0	ns	245.2 ± 355.0	176.5 ± 216	ns	611.8 ± 671.0	468.1 ± 707	ns	585.3 ± 1055.8	415.2 ± 644.8	ns	214.5 ± 306.4	159.4 ± 205.0	ns
NS3	IgM	Seroc	92.3	84.6	ns	100.0	100.0	-	93.3	86.6	ns	100.0	92.8	ns	100.0	91.6	ns
		Titer	171.0 ± 428.8	33.1 ± 43.9	< 0.001	211.1 ± 300.6	62.18 ± 69.55	0.003	55.7 ± 85.7	23.6 ± 14.2	0.040	94.7 ± 146.0	132.3 ± 334.7	ns	214.3 ± 297.3	110.6 ± 192.2	ns
	IgA	Seroc	76.9	50.0	0.008	66.6	60.0	ns	66.6	26.6	0.030	57.1	42.8	ns	83.3	75.0	ns
		Titer	30.2 ± 87.6	24.1 ± 75.9	< 0.001	83.7 ± 240.4	16.3 ± 18.4	0.009	12.0 ± 7.7	8.2 ± 3.6	0.005	20.3 ± 31.8	19.8 ± 41.4	ns	47.8 ± 82.9	53.1 ± 100.2	ns
	IgG	Seroc	96.1	96.1	-	100.0	100.0	-	100.0	100.0	-	100.0	100.0	-	100.0	100.0	-
		Titer	15907.0 ± 15723.0	9684.0 ± 12663.0	0.002	11881.0 ± 7195.0	6493.0 ± 5575.0	0.001	10695.0 ± 10046.4	5166.0 ± 5304.0	0.020	8135.0 ± 8076.2	4570.0 ± 5277.1	0.030	13893.1 ± 11677.0	8806.2 ± 8510.0	ns
Neutralizing antibody response
Positive (%)			46.2	46.7	ns	66.7	58.3	ns	35.7	14.3	ns	23.1	30.8	ns	41.7	41.7	ns
Infectivity (%)			71.0 ± 77.7	58.7 ± 26.6	ns	52.6 ± 24.7	51.0 ± 20.0	ns	61.7 ± 25.1	76.1 ± 22.8	ns	73.5 ± 29.4	60.8 ± 23.8	0.040	53.2 ± 26.5	53.2 ± 26.5	ns

Seroc: Seroconversion; ns: Not significant. Seroconversion data are presented as percent of samples with detectable antibody responses. Titer and infectivity data are presented as mean ± SD, except for IgA response against the capsid in the control group, which is presented as median ± rank. Statistical values refer to time dependent (week 0 vs week 48) differences in one group (McNemar test and paired t test or Wilcoxon signed rank test). Significant differences were considered for P < 0.05. Positive (%) refers to the percent of samples with detectable neutralizing antibody response. Infectivity (%) = (foci forming units in the presence of antibodies from a patient/foci forming unit in the absence of antibodies) × 100.